AnnaPavlickDOMBA

Hematologic Oncology, Melanoma

Professor of Medicine and Dermatology, Weill Cornell School of Medicine

Overview of Dr. Pavlick

Dr. Anna Pavlick is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including New York-Presbyterian Hospital, New York-Presbyterian Hospital, NewYork-Presbyterian/Columbia University Irving Medical Center, NYU Langone Hospitals, NYC Health + Hospitals / South Brooklyn Health, and NYU Langone Hospital - Brooklyn. She received her medical degree from Rowan University School of Osteopathic Medicine and has been in practice 27 years. Dr. Pavlick accepts several types of health insurance, listed below. She is one of 149 doctors at NYU Langone Hospitals and one of 47 doctors at NYC Health + Hospitals / South Brooklyn Health who specialize in Oncology. She has more than 100 publications and over 500 citings.

Office
1305 York Ave., 12th Floor
New York, NY 10065
Book by Phone+1(929) 334-3685

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1993 - 1996
Hackensack University Medical CenterResidency, Internal Medicine, 1990 - 1993
Rowan University School of Osteopathic MedicineClass of 1990

Certifications & Licensure

NJ State License Current
NY State License 1991 - 2025

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2011-2014
Top Doctors: New York Metro Area Castle Connolly, 2009-2014
New York Magazine: Top Doctors Castle Connolly, 2011, 2014
America's Top Doctors for Cancer Castle Connolly, 2010-2013
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Top MD Consumers Checkbook
Join now to see all

Clinical Trials

BMS-247550 in Treating Patients With Stage IV Melanoma Start of enrollment: 2002 Feb 01
Completed
Phase 2
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery Start of enrollment: 2005 Jun 01
Completed
Phase 2
Abraxane and Temodar Plus Genasense in Advanced Melanoma Start of enrollment: 2006 Nov 01
Unknown status
Phase 1
Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2007 Apr 01
Completed
Phase 2
Study of ADI-PEG 20 in Patients With Advanced Melanoma Start of enrollment: 2007 Jul 01
Completed
Phase 1, Phase 2
A Safety and Efficacy Study of Intravenous 131I-TM601 in Adult Patients With Malignant Melanoma
Terminated
Phase 1, Phase 2
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients Start of enrollment: 2010 Sep 01
Completed
Phase 1, Phase 2
RO4929097 in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma That Can Be Removed by Surgery Start of enrollment: 2010 Sep 01
Withdrawn
Phase 2
Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma Start of enrollment: 2013 Aug 01
Terminated
Phase 2
Phase II Randomized Trial of Ipilimumab Versus Ipilimumab and Radiotherapy in Metastatic Melanoma Start of enrollment: 2013 Jan 01
Terminated
Phase 2
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

Clinical outcomes of adjuvant nivolumab in resected stage III melanoma: comparison of CheckMate 238 trial and real-world data.
Justin C Moser, Shailender Bhatia, Asim Amin, Anna C Pavlick, Keith A Betts
Cancer Immunology, Immunotherapy. 2024-05-07
7 citations
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0.
Anna C Pavlick, Charlotte E Ariyan, Elizabeth I Buchbinder, Diwakar Davar, Geoffrey T Gibney
Journal for Immunotherapy of Cancer. 2023-10-01
2 citations
Germline immunomodulatory expression quantitative trait loci (ieQTLs) associated with immune-related toxicity from checkpoint inhibition.
Robert Ferguson, Vylyny Chat, Leah Morales, Danny Simpson, Kelsey R Monson
European Journal of Cancer. 2023-08-01

Journal Articles

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain
Kim Margolin, Omid Hamid, Christopher D Lao, Anna C Pavlick, Michael A Postow, F Stephen Hodi, Nikhil I Khushalani, Marc S Ernstoff, Hussein A Tawbi, Igor Puzanov, Ahm..., The New England Journal of Medicine

Lectures

A phase II open labeled, randomized study of poly-ICLC matured dendritic cells for NY-ESO-1 and Mean-A peptide vaccination compared to Montanide, in melanoma patients ...
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Texas Nurse, 42, Scratches ‘Birthmark’ and Discovers It Was Actually Dangerous Skin Cancer — Understanding Racial Disparities in CancerMay 4th, 2023
3 Skin Cancer Myths, Busted: Can One Bad Sun Burn Cause Cancer?April 23rd, 2023
Psychiatry Resident Doctor Who Went Viral for His Mental Health Advocacy Says He’s Cancer Free After Surgery for Melanoma; Understanding This Type of Skin CancerNovember 15th, 2021
Join now to see all

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Cofinity PPO
Empire BCBS HMO
Empire BCBS PPO
First Health PPO
GHI PPO
Great West PPO
Healthfirst New York
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment